Nanobiotix (NBTX) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer.

The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical control at The University of Texas MD Anderson Cancer Center.

The treatment was well-tolerated, and investigators concluded that its favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial, the company said.

Following positive results, MD Anderson received US FDA clearance for an additional cohort studying NBTXR3 with chemoradiation. Recruitment for the new cohort is ongoing.

Nanobiotix anticipates that MD Anderson will present full results from the completed study phases at a medical congress in H1 2025.